Identification of Prognostic Factors in 61 Patients With Posttransplantation Lymphoproliferative Disorders

Leblond, Véronique; Dhédin, Nathalie; Mamzer-Bruneel, Marie-France; Choquet, Sylvain; Hermine, Olivier; Porcher, Raphaël; Quoc, Stéphanie Nguyen; Davi, Frédéric; Charlotte, Frédéric; Dorent, Richard; Barrou, B.; Vernant, Jean‐Paul; Raphaël, Martine; Lévy, Vincent

doi:10.1200/jco.2001.19.3.772

Cited by 205 publications

(199 citation statements)

References 27 publications

Supporting

Mentioning

171

Contrasting

Unclassified

Order By: Relevance

“…Other prognostic factors for a better response found in retrospective analyses were a good performance status and detection of EBV in tumor tissue. 22 However, in our study, neither LDH nor other variables classically related with prognosis in immunocompetent patients, such as those included in the IPI or the EBV status, were of prognostic significance.…”

contrasting

confidence: 77%

Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease

González‐Barca

Domingo‐Domenech²,

Capote³

et al. 2007

Haematologica

123

View full text Add to dashboard Cite

contrasting

confidence: 77%

Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease

González‐Barca

Domingo‐Domenech²,

Capote³

et al. 2007

Haematologica

123

View full text Add to dashboard Cite

“…Several categories have been identified according to their clinical presentation, morphology, and molecular features (28,29). Most PTLD are associated with EBV, but EBV-negative cases also have been described and tend to occur later than EBV-positive ones (30). HIV-related NHL are mainly high-grade B cellrelated neoplasms.…”

Section: Discussionmentioning

confidence: 99%

The mutator pathway is a feature of immunodeficiency-related lymphomas

Duval

Raphaël

Brennetot

et al. 2004

Proc. Natl. Acad. Sci. U.S.A.

Self Cite

View full text Add to dashboard Cite

The mutator phenotype caused by defects in the mismatch repair system is observed in a subset of solid neoplasms characterized by widespread microsatellite instability-high (MSI-H). It is known to be very rare in non-Hodgkin lymphomas (NHL), whereas mutator NHL is the most frequent tumor subtype in mismatch repairdeficient mice. By screening a series of 603 human NHL with specific markers of the mutator phenotype, we found here 12 MSI-H cases (12͞603, 2%). Of interest, we demonstrated that this phenotype was specifically associated with immunodeficiency-related lymphomas (ID-RL), because it was observed in both posttransplant lymphoproliferative disorders (9͞111, 8.1%) and HIV infectionrelated lymphomas (3͞128, 2.3%) but not in a large series of NHL arising in the general population (0͞364) (P < 0.0001). The MSI pathway is known to lead to the production of hundreds of abnormal protein neoantigens that are generated in MSI-H neoplasms by frameshift mutations of a number of genes containing coding microsatellite sequences. As expected, MSI-H ID-RL were found to harbor such genetic alterations in 12 target genes with a putative role in lymphomagenesis. The observation that the MSI-H phenotype was restricted to HIV infection-related lymphomas and posttransplant lymphoproliferative disorders suggests the existence of the highly immunogenic mutator pathway as a novel oncogenic process in lymphomagenesis whose role is favored when host immunosurveillance is reduced. Because MSI-H-positive cases were found to be either Epstein-Barr virus-positive or -negative, the mutator pathway should act synergistically or not with this other oncogenic factor, playing an important role in ID-RL. microsatellite instability

show abstract

“…In the present series, this low percentage of EBV-positive PTLD can be related to the high number of PTLD cases occurring later than 24 months after transplantation, as has previously been described. 29 BAFF expression was detected in 92% of the 51 DLBCL cases. This result could reflect ligand-receptor engagement as well as environmental-or cellular-secreted BAFF.…”

Section: Discussionmentioning

confidence: 98%

p52 Activation in Monomorphic B-Cell Posttransplant Lymphoproliferative Disorder/Diffuse Large B-Cell Lymphoma without BAFF-R Expression

Proust¹,

Rince²,

Creidy³

et al. 2011

The American Journal of Pathology

Self Cite

View full text Add to dashboard Cite

Identification of Prognostic Factors in 61 Patients With Posttransplantation Lymphoproliferative Disorders

Abstract: PS and the number of involved sites defined three risk groups in our population. The value of these prognostic factors needs to be confirmed in larger cohorts of patients treated in prospective multicenter studies.

Cited by 205 publications

References 27 publications

Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease

Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease

The mutator pathway is a feature of immunodeficiency-related lymphomas

p52 Activation in Monomorphic B-Cell Posttransplant Lymphoproliferative Disorder/Diffuse Large B-Cell Lymphoma without BAFF-R Expression

Contact Info

Product

Resources

About